Vanta Bioscience Limited (VBS) was originally incorporated as a Private Limited Company on 29th April 2016 and was converted into a Public Limited Company with effect from 17th March 2017.
VBS is a preclinical contract research organization, offering a host of preclinical safety assessment services for clientele from Pharmaceutical, Medical Devices, Nutraceuticals, Feed Additive, Biotech, Agrochemicals, Cosmetics, and Chemical industries. In addition, Company provide risk assessment services for evaluating the safety of the Active Pharmaceutical Ingredients (API), excipients, extractable and leachables including pharmaceutical impurities resulting due to manufacturing process or due to degradation of the product. It also provides expert services for determination of health based exposure limits (e.g. permitted daily exposure (PDE) or allowable daily exposure (ADE) including occupational exposure limits (OEL) for pharmaceutical manufacturers.
The Company is established as a center of excellence for GLP toxicology and safety assessment offering services in India and across the globe. One of the major services of VBS is conducting variety of in vitro (cell, tissue and organisms) and in vivo (animal) toxicology studies for its diverse clients as per various regulatory requirements from across the world. Toxicology is a branch of biology, chemistry, and pharmacology concerned with the study of the adverse effects of chemicals on living organisms. It also studies the harmful ...effects of chemical, biological and physical agents in biological systems that establish the extent of damage in living organisms.
The Company purchased preclinical CRO facility at Gummidipundi, Chennai from Kemin Industries South Asia Private Limited which was named as 'Vanta Bioscience' (a toxicology division and commenced commercial activities in April, 2017. VBS has state of the art facilities and infrastructure necessary for conduct of all kind of toxicology studies for Chemicals, Pharmaceuticals, Cosmetics, Agrochemicals like Pesticides, Insecticides, Excipients, Novel Feed Additives.
In addition, the Company conducts preclinical proof-of-concept (PoC) studies for novel pharmaceuticals and products intended for new indications in variety of animal models of human diseases through a robust process of validation.
In September 2017, the Company came up with a Public Issue of 15,12,000 Equity Shares by raising money from public aggregating to Rs 7.56 Crore.
In 2018-19, Vanta Clinical Research Limited and Vayam Research Solutions Limited became the subsidiaries of the Company.
FAQs on Vanta Bioscience Ltd
1. Can I buy Vanta Bioscience Ltd from PL Capital? ›
Yes, you can invest in Vanta Bioscience Ltd shares directly through PL Capital. Our platform provides a seamless and secure way to buy, hold, and track Vanta Bioscience Ltd stock along with other leading companies listed on the NSE and BSE. Simply open a Demat and trading account with PL Capital, and you’ll be able to trade Vanta Bioscience Ltd as well as diversify your portfolio across equities, mutual funds, IPOs, and more.
2. Does Vanta Bioscience Ltd pay dividends? ›
Vanta Bioscience Ltd does not currently pay dividends. Investors in this case primarily benefit from capital appreciation, where the value of the stock may rise over time depending on business growth and market conditions.
3. What is the current share price of Vanta Bioscience Ltd ? ›
As of
08-Apr-2026 , the share price for Vanta Bioscience Ltd. is ₹ on the NSE (Note: Prices are dynamic and update frequently during market hours).
4. What is the 52-week high and low of Vanta Bioscience Ltd ? ›
The 52-week high and low of Vanta Bioscience Ltd share price is ₹ - ₹ as of
08-Apr-2026 , .
